DNTH103-AU-001
46 evidence topics · 9 sources
Objective
Primary objectives in the Part A and Part B registry record
Secondary objectives in the Part A and Part B registry record
Part C objectives: pharmacokinetics after human normal immunoglobulin G
Objectives stated by the company at study start and at top-line results
Location and study date
Registration, recruitment dates, and status of Parts A and B
Study location, sponsors, and ethics committee
Registration, recruitment dates, and status of Part C
First participant dosed, November 2022
Trial initiation and top-line data dates reported by the company
Study design
Single ascending dose and multiple ascending dose parts
Randomization and blinding of Parts A and B
Part C: open-label, uncontrolled single cohort
First-in-human design described by the company
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Part C eligibility
Treatment
Planned Part A single-dose cohorts
“SAD IV1, 1 mg/kg” (opens the source at this quote in a new tab)
“SAD IV2, 3 mg/kg” (opens the source at this quote in a new tab)
“SAD IV3, 10 mg/kg” (opens the source at this quote in a new tab)
“SAD IV4, 30 mg/kg” (opens the source at this quote in a new tab)
“SAD IV5, 60 mg/kg” (opens the source at this quote in a new tab)
“SAD SC1, 300 mg” (opens the source at this quote in a new tab)
“SAD SC2, 600 mg” (opens the source at this quote in a new tab)
Planned Part B multiple-dose cohorts
Dose cohorts reported as dosed
Part C: intravenous immunoglobulin before a single dose of DNTH103
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary safety endpoints and adverse event grading
Safety as the purpose of a first-in-human study
Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints
“Maximum concentration (Cmax)” (opens the source at this quote in a new tab)
“Terminal elimination half-life (t½)” (opens the source at this quote in a new tab)
“Absolute bioavailability (Fabs)” (opens the source at this quote in a new tab)
“CH50 (complement haemolysis 50%) in serum ex vivo” (opens the source at this quote in a new tab)
“Incidence of anti-drug antibody (ADA) to DNTH103” (opens the source at this quote in a new tab)
Part C: pharmacokinetics as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and sample size basis in the Part A and Part B registry record
Final accrual in the registry records, last updated June 2025
Participants by part reported in January 2024
Participants reported in the annual report filed March 2025
Description of analysis sets
Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations
Results
Participant disposition
Participants who completed dosing, as of December 2023
Completion of treatment after injection site reactions
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetic results: half-life and dose proportionality
Pharmacodynamic results: classical pathway inhibition and simulated steady state
Dose selection for later trials based on phase 1 data
Part C pharmacokinetics after immunoglobulin G
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Overall tolerability, serious adverse events, and infections
Adverse events reported across the eight cohorts
Injection site reactions, infusion events, and vomiting
Antinuclear antibody positivity in the 50 mg/kg intravenous cohort
Part C safety
No evidence found.
Study limitations
Summary
DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.